Physician profile
Gale E Belanger
NPI 1881140671
$4,023.97
in general payments reported to CMS, 2019-2025
20 companies · $873 in 2025
The $873 reported for 2025 was more than what 78% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $684 · 2022: $752 · 2023: $828 · 2024: $888 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,477 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.05 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,199.25 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $586.48 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $550.67 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $278.28 | 2024-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $218.75 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $212.79 | 2023-2025 | Austedo, Austedo Xr, Uzedy |
| Lundbeck LLC | $167.18 | 2021-2025 | Rexulti |
| Corium, LLC | $146.86 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $127.84 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.11 | 2025 | Cobenfy |
| Alkermes, INC. | $99.86 | 2023-2024 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $80.82 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $68.92 | 2023-2025 | Ingrezza |
| Adlon Therapeutics L.P. | $50.79 | 2021 | |
| Supernus Pharmaceuticals, INC. | $33.79 | 2022-2023 | Qelbree |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $23.51 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $21.76 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $16.09 | 2021 | |
| Eisai INC. | $13.86 | 2021 | |
| Alfasigma USA, INC. | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gale Belanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.